MedTrace Logo

TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma

NCT06961786 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2026-03-05

No results posted yet for this study

Summary

This is an open-label, phase 1 trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with lymphocyte-depleting chemotherapy and TILs in metastatic melanoma patients.

Conditions

Interventions

BIOLOGICAL

TILT-123

TNFalpha and IL-2 coding oncolytic adenovirus TILT-123

BIOLOGICAL

TIL

Adoptive T cell therapy with TILs

DRUG

Cyclophosphamide

Lymphocyte-depleting chemotherapy

DRUG

Fludarabine

Lymphocyte-depleting chemotherapy

Sponsors & Collaborators

  • TILT Biotherapeutics Ltd.

    lead INDUSTRY

Principal Investigators

  • Inge Marie Svane · CCIT, Herlev Hospital, Copenhagen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-25
Primary Completion
2026-11-30
Completion
2027-04-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06961786 on ClinicalTrials.gov